fda peptide warning letters september 2025 Letters - Novo NordiskFDA warningletter tirzepatide FDA Peptide Warning Letters September 2025: A Deep Dive into Regulatory Scrutiny

HimsFDA The month of September 2025 marked a significant period of increased regulatory action from the U.S.2025年9月17日—Eli Lilly was sent threewarning lettersabout its glucagon-likepeptide-1 receptor agonist (GLP-1RA) tirzepatide, known under the US brand ... Food and Drug Administration (FDA) concerning peptide-based products, particularly those marketed for weight loss and other therapeutic uses. This intensified enforcement activity is highlighted by the issuance of numerous warning letters and other official communications to a wide array of companies2025年9月9日—WARNING LETTER. September 9, 2025. JulyMD: This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed ....

In a decisive move on September 9, 2025, the FDA significantly ramped up its oversight by issuing more than 50 warning letters to companies involved in the compounding and marketing of GLP-1 receptor agonists and other peptides. This broad action targeted telehealth-based businesses and compounding pharmacies that were found to be in violation of federal regulations. The agency's focus was on deceptive advertising and the marketing of unapproved drugs.2026年1月21日—The first-listed example may indicate thatFDAis relaxing the stance it took just six months ago in its July2025 Warning Letterto WHOOP, Inc. For instance, letters were sent to entities such as Healthy Male and Slendid, specifically addressing their practices.

The FDA's concerns extend to the marketing of compounded peptides as generic alternatives or for unapproved uses.FDA's Wave of Untitled Letters Signals Stricter Scrutiny for ... Several warning letters issued in September 2025 specifically addressed companies marketing compounded GLP-1 agonists.2025年10月1日—OnSeptember9,2025, the U.S. Food and Drug Administration (“FDA...FDAreleased around 80warning letters, which we covered in a separate post. This includes actions taken against companies like JulyMD, underscoring the FDA's commitment to ensuring the safety and efficacy of drugs available to the public. A notable aspect of these actions is the extensive documentation of these issues, with the FDA publishing these letters on its Warning Letter database.

Eli Lilly and Company also found itself at the center of FDA scrutiny, receiving multiple warning letters in September 2025. One such FDA warning letter sent to Eli Lilly and Company (Lilly) on Sept2025年9月11日—FDA Sends 100 Cease-and-Desist Letters: A Warning to Industry.September 11, 2025... The FDA used to send more than a hundred warning letters .... 9, 2025, pertained to their direct-to-consumer programs. The agency highlighted concerns regarding the coadministration of tirzepatide with other GLP-1 receptor agonists, stating it is not recommended.Enforcement Climate:FDAhas signaled an aggressive stance –warningcompounding pharmacies vialettersand guidance that compounding thesepeptides... This indicates a broader regulatory interest in the marketing and associated claims made for established pharmaceutical products, not just compounded ones. Similar concerns were raised in other communications to Eli Lilly and Company, referencing MARCS-CMS numbers like 716485 and 716475, both dated September 09, 2025.Regulatory Oversight, FDA Warning Letters, False ...

The FDA's enforcement actions in September 2025 were not limited to domestic oversight. The agency also reported issuing import alerts to prevent potentially dangerous products from entering the country. On September 05, 2025, the FDA established a “green list” import alert to aid in this effort. This proactive measure reflects a comprehensive strategy to protect Americans from illegal and unapproved drug products.

The sheer volume of these regulatory actions is significant. Reports indicate that by Tuesday, September 16, 2025, the FDA had posted a substantial number of communications, including approximately 80 warning letters and numerous untitled letters. This surge in enforcement activity, described as a targeted initiative to combat deceptive drug advertising, was partly spurred by a presidential memorandum issued on September 9, 2025FDA puts compounded weight loss drug advertising in its .... This memorandum set forth the administration's commitment to addressing regulatory violations in the pharmaceutical sector.

These FDA peptide warning letters September 2025 serve as a critical warning to the industry. Companies like Hims and Hers have also been subjects of FDA attention regarding their marketing practices2025年9月11日—FDA Sends 100 Cease-and-Desist Letters: A Warning to Industry.September 11, 2025... The FDA used to send more than a hundred warning letters .... The agency is specifically targeting misleading advertisements and the sale of unapproved drugs containing active ingredients such as semaglutide, tirzepatide, and retatrutide. The FDA has made it clear that drugs falsely labeled "for research" but intended for human consumption are subject to strict regulatory review.

The FDA's proactive stance is evident in its comprehensive approach, which includes not only issuing warning letters but also utilizing other enforcement tools. For example, on September 11, 2025, the FDA announced the issuance of 100 cease-and-desist letters, signaling a robust effort to curb illicit drug marketing. The agency's actions in 2025 demonstrate a clear trend towards stricter scrutiny of drug advertising and promotion, especially for peptides and related compounds. This intensified regulatory climate, marked by numerous warning letters and increased enforcement, underscores the FDA's commitment to safeguarding public health2025 Year in Review: FDA Drug and Device Advertising .... The FDA has stated its intention to continue this rigorous oversight throughout 2025 and beyond.